Bempedoic Acid (Nilemdo) Drug Interactions

Bempedoic Acid (Nilemdo) Drug Interactions

Bempedoic acid (Nilemdo) may interact with other medicines; therefore, it is essential to inform the physician of all medications currently being used. Key interactions include: ① Statins (atorvastatin, rosuvastatin, simvastatin, etc.) – the risk of myopathy is increased with concomitant use, especially simvastatin >40 mg/day which is contraindicated; when combining, use low-to-moderate intensity statins and closely monitor for muscle symptoms. ② Bosentan (for pulmonary arterial hypertension) – may affect the metabolic clearance of bempedoic acid. ③ Fimasartan (antihypertensive) – may alter renal excretion. ④ Anti-hepatitis C drugs (asunaprevir, glecaprevir, etc.) – potential competition for drug transporters exists. ⑤ Fibrates (fenofibrate, etc.) – monitor lipid profile and liver function during combination therapy. In addition, interactions with commonly used drugs such as warfarin and digoxin are not yet clearly defined, but it is advisable to consult a pharmacist before starting any new medication. Patients should keep a complete medication list for the physician to assess risks.

Bempedoic Acid (Nilemdo) Use in Special Populations

Bempedoic acid (Nilemdo) is contraindicated during pregnancy. Since cholesterol is essential for fetal development, inhibiting its synthesis may cause teratogenicity. Therefore, women of childbearing potential must have a negative pregnancy test before initiating therapy and use effective contraception (combination of barrier methods or hormonal contraception is recommended). If oral contraceptives are used, when severe diarrhoea or vomiting lasting more than 2 days occurs, drug absorption may be affected, and an additional barrier method (e.g., condom, diaphragm) should be used for at least 7 days after symptom resolution. If menstruation is delayed or pregnancy is suspected during treatment, stop the drug immediately and contact the physician. Those planning pregnancy should inform the doctor in advance to switch to a lipid-lowering regimen safe for pregnancy (usually suspending the medication). Breastfeeding women should also exercise caution, as bempedoic acid may be excreted into breast milk; human data are lacking, so it is recommended to weigh the benefits and risks under medical guidance, or consider interrupting breastfeeding.

Bempedoic Acid (Nilemdo) Recommended Dosage and Administration

The standard dose is one tablet (180 mg) once daily. The tablet should be swallowed whole, not crushed or chewed, and can be taken with or between meals, independent of food intake, but it is recommended to take it at the same time each day to maintain steady-state plasma concentrations. Missed dose principle: if the dose is missed later in the day, it can be taken immediately, and the next day's dose should be taken at the usual time; if the previous day's dose was forgotten, take a single dose at the usual time the next day – do not double the dose. The treatment course is long-term continuous therapy; do not stop without medical advice, as LDL‑C may return to pre-treatment levels upon interruption. The drug does not require special storage conditions but should be protected from light and moisture. Patients should develop a habit of taking the medication at a fixed time daily, using pill boxes or mobile reminders to improve adherence.